Back to search
FDAFDA · Food and drugs·Recall number D-0229-2022

Cefixime Capsules 400 mg, 50 capsules bottles, Rx Only, Manufactured by: Alken Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories LLC, Parsippany, NJ, 07054 NDC 67877-584-50

Published November 17, 2021 · Recall initiated: November 3, 2021

Summary

FDA records drug Class II recall D-0229-2022, published November 17, 2021 and initiated November 3, 2021. Recalling firm: Ascend Laboratories LLC; Status: Terminated; Reported quantity: 4104 bottles; Lot: Lot 20140282, exp Dec 2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if CEFIXIME has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEFIXIME
Manufacturer
Ascend Laboratories LLC
Distributor
Nationwide
Lot
Lot 20140282, exp Dec 2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cefixime Capsules 400 mg, 50 capsules bottles, Rx Only, Manufactured by: Alken Laboratories Ltd., Mumbai - 400 013, India, Distributed by: Ascend Laboratories LLC, Parsippany, NJ, 07054 NDC 67877-584-50 recalled?

Yes. FDA published recall D-0229-2022 on November 17, 2021. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEFIXIME.